Skye Bioscience, Inc. — Form SCHEDULE 13D/A
Filed September 24, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
5AM Partners VII, LLC filed an amended Schedule 13D/A for Skye Bioscience, Inc. on September 24, 2026. The document is a procedural amendment to a prior beneficial ownership disclosure; specific share counts, percentages, or transaction amounts are not detailed in the header metadata provided.
Why this rating
Schedule 13D/A amendments are routine disclosure updates. Without visible new ownership %, transactions, or material changes in the filing excerpt, this appears administrative. Relative to $129.5M market cap, immaterial unless amendment reveals major stake shift.
See more from September 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.